ASCO Conference Coverage

Oncologists Still Avoid Discussing Cost of Care

(Medscape Medical News) Aug 7, 2017 - Many professional medical organizations that provide guidance for cancer care now advocate a discussion of cost, including the American Society of Clinical Oncology (ASCO), which has urged physicians to do so since 2009. Few clinicians do, however, according to several sets of data.

read article (free registration required)

Biomarkers Set Stage for Next-Gen NSCLC Tx

(MedPage Today/ASCO) Aug 4, 2017 - The ongoing discoveries of biomarkers for non-small cell lung cancer (NSCLC) are moving at a rapid pace as researchers identify new candidates for detection, treatment, and therapeutic response.

read article (free registration required)

Commentary—Peter Bach: Cancer Drugs Not Working Hard Enough for the Money

(Medscape Medical News) July 10, 2017 - "Value is declining very rapidly in a way that almost ensures that what scientific advances we can make will be outstripped by our spending."

read article (free registration required)

Pembrolizumab Flat Dosing Wastes Nearly $1 Billion Annually

(Medscape Medical News) June 26, 2017 - The new immunotherapies are expensive drugs, but a new study suggests that they are costing more than they need to because of flat, rather than personalized, dosing.

read article (free registration required)

Proposed 2018 QPP Rule Adds Flexibility, but Questions on Medicare Part B Drugs Provision Remain

(ASCO in Action) June 21, 2017 - The Centers for Medicare & Medicaid Services (CMS) released its proposed rule outlining changes to the Quality Payment Program (QPP) for 2018. The proposal became available on June 20 and is scheduled to be published in the Federal Register on June 30.

read article

Medical Organizations Ask for FDA Guidance on Plain Language Summaries of Clinical Trials

(ASCO in Action) June 21, 2017 - ASCO joined more than 35 other organizations, including professional societies, patient advocacy groups, and research institutions, to encourage the U.S. Food and Drug Administration (FDA) to develop a guidance on plain language summaries for clinical trials results.

read article

CancerLinQ® Featured at Annual Meeting Session on Economics of Cancer Care

(ASCO in Action) June 19, 2017 - On June 1 and June 2, CancerLinQ LLC Chief of Strategic Alliances Jennifer L. Wong spoke at the “Big Data in Oncology” session at an ASCO Annual Meeting 2017 seminar titled “The Economics of Cancer Care.”

read article

From ASCO to ICLIO to Your Program—Immunotherapy Moves into the Community

(ACCCBuzz Blog) June 16, 2017 - Once again immuno-oncology (I-O) was center stage at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting (June 2-6, 2017) where more than 250 presentations featured checkpoint inhibitors.

read article

ASCO 2017: 4 Ways Treatment Could Change Following World’s Largest Cancer Conference

(Cancer Research UK/Science blog) June 19, 2017 - Targeted treatment up front improves survival for advanced prostate cancer, and we predict a change in thinking for precision cancer medicine.

read article

Cancer's Big Infrastructure Problem

(Forbes) June 15, 2017 - We need to do more than just raise cancer drug prices yet again. We need to invest in the kind of infrastructure that will make it possible to test many of these medicines, and speed up innovation further.

read article

Possible Role for Immunotherapy in Early-Stage Breast Cancer

(Medscape Medical News) June 15, 2017 - Immune checkpoint blockade may have a role in the presurgery treatment of high-risk, early-stage breast cancers, according to results from a phase 2 trial presented here at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting.

read article (free registration required)

In Lymphoma, Best Partner With Rituximab Still in Question

(Medscape Medical News) June 15, 2017 - Results from the long-term follow-up of frontline therapy for patients with indolent non-Hodgkin's lymphoma (iNHL) show the long-term benefits of chemotherapy in combination with rituximab (Rituxan, Roche/Genentech).

read article (free registration required)

Lots of Unneeded Interventions in Early Breast Cancer

(Medscape Medical News) June 14, 2017 - Among women who have been treated for early-stage breast cancer and are under surveillance, more than a third (37%) receive what are very likely to be unneeded tumor-marker blood tests, according to new research from the state of Washington.

read article (free registration required)

Chinese Cancer Drug One Step Closer To The International Market

(The New Economy [UK]) June 12, 2017 - Shanghai-based pharmaceutical company Hutchison China MediTech (Chi-Med) announced on June 12 that the China Food and Drug Administration had accepted an application to consider its new drug Fruquintinib as a treatment for colorectal cancer.

read article

Roche CEO Still Optimistic On New Breast Cancer Drug

(Reuters) June 11, 2017 - Roche is convinced a new breast cancer drug will have a significant role in treating the disease despite recent trial results that disappointed analysts, the Swiss drugmaker's chief executive said in an interview published on Sunday.

read article

Cancer Drug Prices Are So High That Doctors Will Test Cutting Doses

(Washington Post/To Your Health) June 8, 2017 - A group of prominent cancer doctors is planning a novel assault on high drug costs, using clinical trials to show that many oncology medications could be taken at lower doses or for shorter periods without hurting their effectiveness.

read article (free registration required)

'Tumor Agnostic' Cancer Drugs Seen Boosting Wider Genetic Tests

(Reuters) June 9, 2017 - Last month, Merck's immunotherapy Keytruda became the first cancer treatment ever to win U.S. approval based on whether the tumor carried a specific genetic glitch, irrespective of the tumor's location.

read article

Precision Oncology Drug Yields Impressive Results, Showing Power Of Cancer Genomics

(Forbes) June 9, 2017 - One of the most remarkable papers from this year’s big cancer meeting drew attention to an experimental drug called larotrectinib.

read article

Roche Drops NewLink IDO Inhibitor After ASCO

(BioPharma Dive) June 8, 2017 - After a somewhat disappointing performance at the American Society of Clinical Oncology meeting in Chicago last week, Roche has returned the rights to NewLink Genetics’ IDO inhibitor GDC-0919.

read article

New Studies Rely on the Internet for Help Treating Cancer Patients

(Wall Street Journal) June 6, 2017 - New reports on two web-based cancer initiatives provide fresh evidence for the potential of the internet to give patients more influence over the research and treatment of their diseases.

read article (paid subscription required)
Next Page